Revolution Medicines Inc

For the period ended Dec 31, 2024. Filed Feb 26, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 26, 2025

RVMD$193.06-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

	Year Ended December 31,
	2024	2023	2022
Revenue:
Collaboration revenue	$—	$11,580	$35,380
Total revenue	—	11,580	35,380
Operating expenses:
Research and development	592,225	423,144	253,073
General and administrative	97,299	75,621	40,586
Total operating expenses	689,524	498,765	293,659
Loss from operations	(689,524)	(487,185)	(258,279)
Other income (expense), net:
Interest income	86,883	47,482	9,154
Other expense	(2,528)	(303)	—
Change in fair value of warrant liability and contingent earn-out shares	4,323	115	—
Total other income, net	88,678	47,294	9,154
Loss before income taxes	(600,846)	(439,891)	(249,125)
Benefit from income taxes	753	3,524	420
Net loss	$(600,093)	$(436,367)	$(248,705)
Net loss per share attributable to common stockholders, basic and diluted	$(3.58)	$(3.86)	$(3.08)
Weighted-average common shares used to compute net loss per share, basic and diluted	167,737,672	113,149,869	80,626,525
Comprehensive loss:
Net loss	$(600,093)	$(436,367)	$(248,705)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net	777	2,324	(1,404)
Comprehensive loss	$(599,316)	$(434,043)	$(250,109)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.